Cargando...

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor

Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with non-valvular atrial fibrillation (NVAF) and symp...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Bounameaux, Henri, Camm, A. John
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2014
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4107274/
https://ncbi.nlm.nih.gov/pubmed/25034361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-014-0261-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!